SignalCorporate
Novo Nordisk, Eli Lilly Report GLP-1 Signals of Slowed Biological Aging at ARDD
Novo Nordisk and Eli Lilly report GLP-1 signals of slowed biological aging at ARDD.
Context
What happened: Novo Nordisk and Eli Lilly reported GLP-1 signals of slowed biological aging at ARDD, per a MedPath trial news article.
Why it matters: The report links the companies' GLP-1 drugs to aging-related findings presented at the ARDD event.
Key numbers: Hacker News post: 4 points, 1 comment.
What changed
Novo Nordisk and Eli Lilly reported GLP-1 signals of slowed biological aging at ARDD, per a MedPath trial news article.
Why it matters
The report links the companies' GLP-1 drugs to aging-related findings presented at the ARDD event.
Key numbers: Hacker News post: 4 points, 1 comment.